red spot at injection site tirzepatide reactions Injection site reaction -anyone else?
Description
and avoiding combination with other GLP-1 receptor agonists or DPP-4 inhibitors
According to the Mounjaro Prescribing Information, these include nausea (17-22%), diarrhea (13-17%), decreased appetite (10-14%), vomiting (6-10%), constipation (5-7%), and dyspepsia (5-7%)
The reported incidence of pancreatic cancer varied from study to study at 0.682.94% 2,9,10,12,15
Biweekly personal health coaching
Your schedule will resemble this: Weeks 1-4 at 0.25 mg, Weeks 5-8 at 0.5 mg, Weeks 9-12 at 1 mg, and finally, Weeks 13-16 at 1.7 mg
